Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CYLD_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CYLD_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CYLD_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CYLD_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006049116 | Oral cavity | LP | regulation of cell projection assembly | 66/4623 | 188/18723 | 8.62e-04 | 7.49e-03 | 66 |
GO:007030216 | Oral cavity | LP | regulation of stress-activated protein kinase signaling cascade | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
GO:003806112 | Oral cavity | LP | NIK/NF-kappaB signaling | 52/4623 | 143/18723 | 1.20e-03 | 9.66e-03 | 52 |
GO:003287216 | Oral cavity | LP | regulation of stress-activated MAPK cascade | 66/4623 | 192/18723 | 1.60e-03 | 1.23e-02 | 66 |
GO:007050715 | Oral cavity | LP | regulation of microtubule cytoskeleton organization | 53/4623 | 148/18723 | 1.60e-03 | 1.23e-02 | 53 |
GO:003052219 | Oral cavity | LP | intracellular receptor signaling pathway | 87/4623 | 265/18723 | 1.63e-03 | 1.25e-02 | 87 |
GO:003320913 | Oral cavity | LP | tumor necrosis factor-mediated signaling pathway | 38/4623 | 99/18723 | 1.72e-03 | 1.31e-02 | 38 |
GO:012003217 | Oral cavity | LP | regulation of plasma membrane bounded cell projection assembly | 64/4623 | 186/18723 | 1.81e-03 | 1.37e-02 | 64 |
GO:003461219 | Oral cavity | LP | response to tumor necrosis factor | 83/4623 | 253/18723 | 2.10e-03 | 1.54e-02 | 83 |
GO:00108031 | Oral cavity | LP | regulation of tumor necrosis factor-mediated signaling pathway | 21/4623 | 47/18723 | 2.17e-03 | 1.58e-02 | 21 |
GO:007135619 | Oral cavity | LP | cellular response to tumor necrosis factor | 76/4623 | 229/18723 | 2.24e-03 | 1.62e-02 | 76 |
GO:003287316 | Oral cavity | LP | negative regulation of stress-activated MAPK cascade | 22/4623 | 51/18723 | 2.96e-03 | 2.03e-02 | 22 |
GO:007030316 | Oral cavity | LP | negative regulation of stress-activated protein kinase signaling cascade | 22/4623 | 51/18723 | 2.96e-03 | 2.03e-02 | 22 |
GO:006082815 | Oral cavity | LP | regulation of canonical Wnt signaling pathway | 82/4623 | 253/18723 | 3.23e-03 | 2.18e-02 | 82 |
GO:003011115 | Oral cavity | LP | regulation of Wnt signaling pathway | 103/4623 | 328/18723 | 3.29e-03 | 2.21e-02 | 103 |
GO:0043433 | Oral cavity | LP | negative regulation of DNA-binding transcription factor activity | 61/4623 | 185/18723 | 6.68e-03 | 3.89e-02 | 61 |
GO:006007015 | Oral cavity | LP | canonical Wnt signaling pathway | 94/4623 | 303/18723 | 6.97e-03 | 3.96e-02 | 94 |
GO:200123326 | Oral cavity | EOLP | regulation of apoptotic signaling pathway | 99/2218 | 356/18723 | 1.25e-16 | 1.25e-13 | 99 |
GO:009719326 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway | 84/2218 | 288/18723 | 1.29e-15 | 7.05e-13 | 84 |
GO:200124226 | Oral cavity | EOLP | regulation of intrinsic apoptotic signaling pathway | 54/2218 | 164/18723 | 8.03e-13 | 2.09e-10 | 54 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0466811 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa046689 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa046258 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
hsa040644 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa043806 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa04622 | Oral cavity | OSCC | RIG-I-like receptor signaling pathway | 41/3704 | 71/8465 | 1.20e-02 | 2.63e-02 | 1.34e-02 | 41 |
hsa0466816 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa0462512 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
hsa0406411 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0438011 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa046221 | Oral cavity | OSCC | RIG-I-like receptor signaling pathway | 41/3704 | 71/8465 | 1.20e-02 | 2.63e-02 | 1.34e-02 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYLD | SNV | Missense_Mutation | | c.1787N>A | p.Gly596Asp | p.G596D | Q9NQC7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
CYLD | SNV | Missense_Mutation | | c.815N>T | p.Pro272Leu | p.P272L | Q9NQC7 | protein_coding | deleterious(0) | possibly_damaging(0.767) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
CYLD | SNV | Missense_Mutation | novel | c.590T>C | p.Val197Ala | p.V197A | Q9NQC7 | protein_coding | tolerated(0.08) | probably_damaging(0.992) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYLD | SNV | Missense_Mutation | | c.1240N>C | p.Asn414His | p.N414H | Q9NQC7 | protein_coding | deleterious(0.02) | possibly_damaging(0.832) | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
CYLD | SNV | Missense_Mutation | rs538206791 | c.100N>G | p.Gln34Glu | p.Q34E | Q9NQC7 | protein_coding | tolerated_low_confidence(0.11) | benign(0.066) | TCGA-OL-A66I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
CYLD | insertion | Frame_Shift_Ins | novel | c.1584_1585insCCTGTTTTAATGCTTGTAGAAATGGTGCGGGAAAGCCCGTTTAACC | p.Lys529ProfsTer29 | p.K529Pfs*29 | Q9NQC7 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYLD | insertion | Frame_Shift_Ins | novel | c.2766_2767insTGGTA | p.Leu923TrpfsTer32 | p.L923Wfs*32 | Q9NQC7 | protein_coding | | | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
CYLD | insertion | Nonsense_Mutation | novel | c.2767_2768insAAGCACAAGTGACAGGAGATATCTAGTAAAGACTT | p.Leu923GlnfsTer9 | p.L923Qfs*9 | Q9NQC7 | protein_coding | | | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
CYLD | SNV | Missense_Mutation | novel | c.1411G>C | p.Glu471Gln | p.E471Q | Q9NQC7 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CYLD | SNV | Missense_Mutation | novel | c.280N>C | p.Glu94Gln | p.E94Q | Q9NQC7 | protein_coding | tolerated(0.18) | probably_damaging(0.986) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |